| Literature DB >> 16011307 |
Mototsugu Oya1, Hirotaka Asakura, Ryuichi Mizuno, Ken Marumo, Masaru Murai.
Abstract
A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-alpha2b (Intron A). A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion. Interleukin-2 (Imunace) was administered without any response. Finally, he was treated by natural IFN-alpha (OIF). The pulmonary lesion achieved a partial response after 11 months of treatment. Because IFN-alpha preparations include different subtypes, changing the use of IFN-alpha preparations may thus be a potentially useful option for the successful immunotherapy of RCC.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16011307 DOI: 10.2220/biomedres.26.135
Source DB: PubMed Journal: Biomed Res ISSN: 0388-6107 Impact factor: 1.203